Bull’s Eye Report: Biogen Idec (BIIB)

Biogen Idec (BIIB), along with others in the biotech space, is looking very strong, with momentum that puts it ahead of the pack. More 

Changing U.S. Demographics Mean a Decades-Long Healthcare Boom

The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs. More 

Bull’s Eye Report:Isis Pharmaceuticals (ISIS)

Biotechs are blowing up -- and ISIS Pharmaceuticals (ISIS) is showing an attractive buy right now with potential 12% upside. More 

Bull’s Eye Report: Pharmacyclics (PCYC)

Pharmacyclics (PCYC) is our top pick today as an outperformer in the biotech space. More 

Bull’s Eye Report: Pharmacyclics (PCYC)

Biotech is a hot industry that's extremely volatile right now. Get on the right side of that volatility with Pharmacyclics (PCYC). More 

Bull’s Eye Report: United Therapeutics Group (UTHR)

United Therapeutics (UTHR) should move back up to recent highs around $63, and today presents a great opportunity to get in. More 

Make a Straightforward Play in Biotech

The iShares Nasdaq Biotechology Index Fund is a great way to get into biotechs ... just not now. It's due for a buyers' exhaustion break, so wait and keep watch. More